Option chain shows key data for Elicio Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Elicio Therapeutics.

Elicio Therapeutics (NASDAQ:ELTX) Stock, Option Chain

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Recent Gains

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATPC

BDMD

CGBS

CRKN

DWTX

New Oriental Education & Technology Group

ELTX

EONR

FFWM

GOEV

IROQ

ORKT

RSKD

RYAM

SWKH

TMCI

TPET

TTGT

VATE

Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

ALVO

BBGI

BCAX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TXNM

VIAV

WILC

Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket

Cancer-Image by PDPics from Pixabay-

Biotech

Equities

Health Care

Financing

Offerings

General

Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors.

Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?

Elicio Therapeutics Inc

Press Releases

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Earnings

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atossa Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Biomea Fusion

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Climb Bio

Coya Therapeutics

Caribou Biosciences

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

HilleVax

Immunic

OncoCyte

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Sutro Biopharma

TScan Therapeutics

Vigil Neuroscience

Vor Biopharma

Vaxart

XBiotech

Jones Trading

HC Wainwright & Co.

Screenshot 2024-06-07 at 5.22.00 PM

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors

Screenshot 2024-04-10 at 5.39.01 PM

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry

Screenshot 2024-04-04 at 5.26.54 PM

Unlocking The Power Of Immunotherapy: Elicio Therapeutics&#39; (NASDAQ: ELTX) Novel AMP Platform

Comments

Elicio Therapeutics

Elicio Therapeutics (ELTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga